Search bioRxiv⌕ Search

Biology subjects

Khanal, J.

Publications and source records attributed to Khanal, J..

2 recordsLinked to original sources

Analysis of the phosphorylation networks characterizing distinct phenotypic states in glioblastoma cell Populations

Cancer cells, including the most aggressive brain cancer, glioblastoma, can exhibit a high degree of phenotypic plasticity. However, it is not well understood whether and how distinct phenotypic states might be associated with or driven by specific signaling processes. Here, we use a novel approach to the identification of phenotype-specific signaling networks in cells undergoing the Go-or-Grow switch in populations of GBM cell lines. We find that the transition to invasive spread may be associated with the onset of DNA damage response, cell cycle arrest, and activation of the AKT-mTOR signaling. We reconstructed the large-scale signaling networks, revealing integration of diverse pathways and possible feedback interactions mediating phenotypic stability. We further show that phosphorylation outcomes may be preferentially mediated by 14-3-3 proteins, previously implicated in stress response and control of the cell cycle. Finally, we demonstrate that the phenotype-specific phospho-site signatures have predictive power for disease-free patient survival. This study paves the way for a more comprehensive understanding of phenotypic plasticity in GBM and other aggressive cancers.

systems biology↗

De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma

Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma, leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia, they appear less active in aggressive glioma, underscoring the need for alternative treatment strategies. Through a chemical synthetic lethality screen, we discovered that IDH1 mutant glioma cells are hypersensitive to drugs targeting enzymes in the de novo pyrimidine nucleotide synthesis pathway, including dihydroorotate dehydrogenase (DHODH). We developed a genetically engineered mouse model of mutant IDH1-driven astrocytoma and used it and multiple patient-derived models to show that the brain-penetrant DHODH inhibitor BAY 2402234 displays monotherapy efficacy against IDH mutant gliomas. Mechanistically, this vulnerability selectively applies to de novo pyrimidine, but not purine, synthesis because glioma cells engage disparate programs to produce these nucleotide species and because IDH oncogenes increase DNA damage upon nucleotide pool imbalance. Our work outlines a tumor-selective, biomarker-guided therapeutic strategy that is poised for clinical translation.

cancer biology↗